MT2017-45 :CAR-T Cell Therapy for Heme Malignancies

Condition(s)
Leukemia Lymphoma

Age Group
0-9 years 10-17 years 18-26 years

Phase(s)
2

Drug Pill Drug
Fludarabine Cyclophosphamide

Biological treatment cell Biological
Kymriah Yescarta
Trial Summary & Details
Ages: Child, Adult, Older Adult
Condition: Acute Lymphoblastic Leukemia, Large B-cell Lymphoma

This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.

Status
Recruiting
Location(s)
Masonic Cancer Center, University of Minnesota, MN
Contact
Timothy Krepski, RN
612-273-2800